Clarithromycin v Ciprofloxacin Added to Rifampicin + Ethambutol, for Opportunist Mycobacterial Pulmonary Disease
Status:
Completed
Trial end date:
2004-09-01
Target enrollment:
Participant gender:
Summary
To date key drugs in the treatment of MAIS, M.malmoense and M.xenopi (Opportunist
Mycobacteria have been rifampicin and ethambutol. Clarithromycin and Ciprofloxacin are active
in vitro against these species of mycobacteria. The primary aim of this study was to compare
these to agents as supplements to rifampicin and ethambutol. A secondary aim was to assess
the vale of immunotherapy with M.vaccae.